RHHBY - Roche and Hitachi High-Tech extend their 46-year partnership paving the way for further breakthroughs in diagnostic testing | Benzinga
- Renewed partnership combines best in class engineering capabilities with cutting edge science to accelerate the availability of new solutions for customers and patients worldwide
- Upcoming launches of the new cobas® c703 & ISE neo units and cobas® Mass Spec solution are testament to the partnership's dedication to continued innovation
- The new 10-year contract will focus on strengthening the partnership for continued transformative innovation for patients
BASEL, Switzerland, May 27, 2024 /PRNewswire/ -- Roche announced today that Hitachi High-Tech and Roche have extended their partnership, committing to at least 10 years of additional collaboration. Bringing together the companies' expertise and track record in diagnostics innovation, engineering and manufacturing, the renewed contract further strengthens the two companies' long lasting partnership.
Together, the companies have delivered significant innovations that paved the way for industry-leading in-vitro diagnostic solutions. From revolutionising the clinical lab with the world's first multi-channel analyser, to the automation of immunology, the collaboration has led to groundbreaking innovations that have enabled labs and healthcare systems to overcome delivery challenges and get patients the care they need.
"I am delighted that with this new agreement, Roche and Hitachi High-Tech can continue to push the boundaries of medical technology and transform patient care", commented Palani Kumaresan, Head of Roche Diagnostic Solutions. "Together, we have built an unrivalled installed base of more than 84,000 diagnostic platforms around the globe. This brings both speed and scale to testing for our customers, helping them to better serve patients' needs."
"Hitachi High-Tech and Roche have worked together to expand in the field of in-vitro diagnostics by boldly pursuing innovations. The renewal of this agreement demonstrates both companies' commitment to the future of the global diagnostics market. We look forward ...